Efficacy evaluation of intravitreal aflibercept for polypoidal choroidal vasculopathy

Not Applicable

• Conditions: polypoidal choroidal vasculopathy

• Registration Number: JPRN-UMIN000010461
• Lead Sponsor: Yokohama City University Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-04-12
• Study Completion: 2014-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1) Lesion size >=12 disc area (1 disc rea is 30.5mm2). 'Lesion' includes hemorrhage, scar, and CNV. 2) Area of subretinal hemorrage in study eye>=50% of total lesion area 3) Area of scar or fibrosis in study eye>=50% of total lesion area 4) RPE tear in study eye 5) Stage 3 or 4 macular hole in study eye 6) Administration of triamcinolone to study eye within 6 months prior to this study 7) Administration of dexamethasone to study eye within 30 days prior to this study 8) Intraocular surgery to study eye within 6 months prior to this study 9) Any history of vitrectomy in study eye 10) Any inflammation or infection in intra-or extra-ocular tissue in either eye 11) History of uveitis in either eye 12) Allergy to fluorescein, indocyanine or iodine 13) pregnant women and nursing mothers 14) Patients who were judged by docters to be inappropriate for this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified